Raise standards for preclinical cancer research
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index; 3 of the 9 sources its claims cite were checked for support.
Overview
CoChat Summary
TL;DR
This Nature Comment argues that many landmark preclinical oncology findings are not reproducible and calls for higher standards in methods, reporting, and incentives. It reports that Amgen confirmed only 6 of 53 landmark papers (11%) and cites Bayer’s finding that about 25% of published preclinical studies could be validated.
Key findings
- In Amgen’s ten-year retrospective analysis, scientific findings were confirmed in only 6 of 53 “landmark” preclinical cancer papers (11%); non-reproduced studies often lacked blinding, relied on single experiments such as one Western blot, or presented selected data.
- Bayer HealthCare reported that only about 25% of published preclinical studies could be validated to the point at which projects could continue; published cancer research represented 70% of the studies analysed in that report, with possible overlap with Amgen’s 53 papers.
- Citation data showed non-reproduced articles in journals with impact factor >20 had a mean of 248 citations (range 3–800) versus 231 (range 82–519) for reproduced articles; for impact factor 5–19, non-reproduced articles had a mean of 169 citations (range 6–1,909) versus 13 (range 3–24) for reproduced articles.
- The authors recommend reporting negative data, blinding preclinical experiments, validating reagents, repeating critical experiments, avoiding single cell lines or models, requiring patient-selection biomarkers, and changing academic incentives.
Methods
- This is a Nature Comment/perspective, not a primary experimental study; it synthesizes Amgen’s ten-year retrospective analysis of experiments performed prospectively and cites a Bayer HealthCare report.
- Amgen selected 53 “landmark” papers describing completely new approaches or alternative clinical uses, attempted confirmation, used additional models, contacted original authors, exchanged reagents, and repeated experiments under the authors’ direction, occasionally in the original investigator’s laboratory.
- The analysis reports counts of confirmed findings and citation metrics from Google Scholar, May 2011; the recommendations are proposed changes rather than tested interventions.
Limitations
- Stated: validation attempts may have failed because of technical differences or difficulties despite efforts to ensure otherwise; additional models were used; when findings could not be reproduced, authors were contacted and experiments were repeated under their direction.
- Stated: papers were deliberately selected as “landmark” and described something completely new, so some data might not hold up; Bayer’s analysed studies may overlap with Amgen’s 53 papers.
- Evident: as a Comment, the text provides no detailed systematic protocol, inclusion criteria, statistical methods, or full dataset; the citation analysis is descriptive and limited to two impact-factor strata.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 1 Not valid · 6 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sadly, clinical trials in oncology have the highest failure rate compared with other therapeutic areas.”
What the sources say
- Partly supportedcites [1] Hutchinson, L. & Kirk, R. Nature Rev. Clin. Oncol. 8, 189–190 (2011). sourceExperimental — accuracy not yet measured
The opening passage of our copy (labelled Abstract; page unavailable) says cancer-drug attrition is much higher than in other therapeutic areas, citing 5% of anticancer agents versus 20% of cardiovascular agents reaching licensure. That comparison covers development from preclinical activity through phase III, not failure rates specifically among clinical trials; it also does not explicitly establish a highest-rate ranking. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although we in the cancer field hoped that this would lead to more effective drugs, historically, our ability to translate cancer research to clinical success has been remarkably low 1 .”
What the sources say
- Supportedcites [1] Hutchinson, L. & Kirk, R. Nature Rev. Clin. Oncol. 8, 189–190 (2011). source
The opening passage (labeled Abstract in our copy; no page given) reports that only 5% of agents with preclinical anticancer activity are licensed after demonstrating sufficient efficacy in phase III testing. It also says cancer drug attrition is much higher than in other therapeutic areas, supporting the claim of historically low translation to clinical success. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In studies for which findings could be reproduced, authors had paid close attention to controls, reagents, investigator bias and describing the complete data set.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For results that could not be reproduced, however, data were not routinely analysed by investigators blinded to the experimental versus control groups.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigators frequently presented the results of one experiment, such as a single Western-blot analysis.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
12 more claims
Create a free account to see all 22 claims and every source verdict.
- It may state two separate claims as one. 2
- Probably not a substantial claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there are other more common sources of unreliability in the literature (41)(42)(43)(44)”
From Misconduct accounts for the majority of retracted scientific publications (2012) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many established scientific results in the social (49, 50) and biomedical (51-53) sciences cannot readily be replicated.”
From Misinformation in and about science (2021) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A landmark study conducted by Glenn Begley and his team in 2012 concluded that most cancer research studies were not reproducible, by alarmingly reporting that 47 of 53 published findings could not be replicated [13].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cell biology, two industrial laboratories reported success replicating the original results of landmark findings in only 11% and 25% of the attempted cases ( 10, 11 ).”
From Estimating the reproducibility of psychological science (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Concerns about reproducibility are widespread across disciplines ( 921 ).”
From Estimating the reproducibility of psychological science (2015) · cites this paper as [10]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Do Pressures to Publish Increase Scientists' Bias? An Empirical Support from US States Data
Fanelli, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010271 · Cited by 805
High drug attrition rates—where are we going wrong?
Hutchinson, L., & Kirk, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.34 · Cited by 517
Drug development and clinical trials—the path to an approved cancer drug
Rubin, E. H., & Gilliland, D. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.22 · Cited by 135
Raising the bar for cancer therapy models
Francia, G., & Kerbel, R. S. (2010) · Nature Biotechnology · doi:10.1038/nbt0610-561 · Cited by 54
Cited by
Items 2,601–2,700 of 2,889
INDUCTION IS NOT ROBUST TO SEARCH
Gollnick, C. (2018) · Amsterdam University Press eBooks · doi:10.2307/j.ctvhrd092.22 · Cited by 3
(2012) · Significance · doi:10.1111/j.1740-9713.2012.00598.x
Zarbin, M. A. (2017) · Translational Vision Science & Technology · doi:10.1167/tvst.6.5.7
“Unfortunately, even highly cited basic science research does not always produce results that are replicated.(1,2) Errors in study design seem to occur more frequently than they should, even in basic research.”
BackgroundPorcine pancreatic ductal epithelial cells transformed with KRAS G12D and SV40T are tumorigenicPreprint
Bailey, K. L., Cartwright, S., Patel, N. S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-268379/v1
19 The Conundrum of Dosimetry: Its Applications to Pharmacology and Biophysics Are Distinct
Miller, W. (2017) · CRC Press eBooks · doi:10.1201/9781315154572-20
(2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813635-5.16001-x
Williams, M., Curtis, M. J., & Mullane, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804725-5.00010-0
Almgren, H., Parsons, N., Bossche, S. V. D., & Marinazzo, D. (2020) · MetArXiv (OSF Preprints) · doi:10.31222/osf.io/9hg3j
What's Wrong with Scientific Publishing, and How We Can Fix ItPreprint
Smith, J. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3129898
Open Science als wissenschaftspolitische Problemlösungsformel?
Franzen, M. (2016) · Springer eBooks · doi:10.1007/978-3-658-05677-3_23-1
Hanna, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-02955-5_1
(2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817443-2.00025-2
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694.012
Halim, A. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816121-0.00001-5
Hoff, D. D. V., & Han, H. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02906-x
“Multiple authors have recently warned all of us that perhaps only 16–25% of new therapeutic science is reproducible [4, 5].”
BackgroundA database of accurate electrophoretic migration patterns for human proteins in cell linesPreprint
Mylonas, R., Potts, A., Waridel, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.22.496709
Scoping Reviews and Their Role in Reducing Research WastePreprint
Khalil, H., Peters, M. D. J., McInerery, P., Godfrey, C., Alexander, L., Evans, C., Pieper, D., Moraes, E., Tricco, A. C., Munn, Z., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4118219
Perdue, W. L., Reus, V. I., van Breemen, R. B., Muchiri, R. N., & Yeamans, R. (2022) · medRxiv · doi:10.1101/2022.08.09.22278588
Software for Neuroimaging Data Analysis
Poline, J., & Kennedy, D. N. (2022) · Springer eBooks · doi:10.1007/978-1-0716-1006-0_538
Interpreting and Implementing Evidence for Quality Research
Cahan, E. M., & Shea, K. G. (2022) · Springer eBooks · doi:10.1007/978-3-031-07105-8_13
Software for Neuroimaging Data Analysis
Poline, J., & Kennedy, D. N. (2014) · Springer eBooks · doi:10.1007/978-1-4614-7320-6_538-1
Park, S. H., Lee, S. B., Park, S., Kim, E. Y., Pizzol, D., Trott, M., Barnett, Y., Koyanagi, A., Jacob, L., Soysal, P., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2183732/v1
Problems of Measurement and Meaning in Biology
Weimer, W. B. (2022) · Palgrave studies in classical liberalism · doi:10.1007/978-3-031-17173-4_4
How to Mitigate Unintentional Misconduct with Samples and Data in Biorepositories
Simeon‐Dubach, D., & Kozlakidis, Z. (2022) · Springer eBooks · doi:10.1007/978-3-030-99680-2_46
Crawford, S., & Hayward-Piatkovskyi, B. (2022) · Medical Research Archives · doi:10.18103/mra.v10i9.3002
Seveljevic-Jaran, D., Antolić, M., Ognjenović, A., Kalliokoski, O., Abelson, K., & Hau, J. (2023) · In Vivo · doi:10.21873/invivo.13060
Balas, E. A., Patel, C., Ewing, B., et al. (2023) · medRxiv · doi:10.1101/2023.01.09.23284360
Võikar, V., Casarotto, P. C., Glerean, E., et al. (2023) · doi:10.31234/osf.io/4dgz5
The future of psychology: Approaches to enhance therapeutic outcomes
Stapleton, P., Baumann, O., & Church, D. (2023) · Frontiers research topics · doi:10.3389/978-2-83251-265-4
Multiversal Methods in Observational Studies: The Case of COVID-19
Tomaselli, V., Cantone, G. G., & Miracula, V. (2022) · Springer proceedings in mathematics & statistics · doi:10.1007/978-3-031-16609-9_22 · Cited by 2
Miller, S. M., Moos, W. H., Munk, B. H., Munk, S. A., Hart, C. P., & Spellmeyer, D. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824304-6.00003-1
Weiner, B. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-24677-7_1
Toxicology Certification: The Need, the Value, and an Evolving Landscape
Donahue, D. A., & Burns‐Naas, L. A. (2023) · International Journal of Toxicology · doi:10.1177/10915818231171834
ЕПОХА ПОСТПРАВДИ У СУЧАСНОМУ СВІТІ: ВИТОКИ ТА ПРИЧИНИ
Коркос, Я. (2023) · Наукові перспективи (Naukovì perspektivi) · doi:10.52058/2708-7530-2023-4(34)-537-554
Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology
Baaz, M., Cardilin, T., Lignet, F., Zimmermann, A., Bawab, S. E., Gabrielsson, J., & Jirstrand, M. (2023) · BMC Cancer · doi:10.1186/s12885-023-10899-y
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.002.0004
May, J. (2023) · Neuroethics · doi:10.1093/oso/9780197648087.002.0006
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0010
May, J. (2023) · Neuroethics · doi:10.1093/oso/9780197648087.002.0007
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0004
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.002.0008
May, J. (2023) · Neuroethics · doi:10.1093/oso/9780197648087.002.0003
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0001
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0009
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0003
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0002
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0006
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0005
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0008 · Cited by 1
May, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197648087.003.0007
May, J. (2023) · Neuroethics · doi:10.1093/oso/9780197648087.002.0010
Estudios de casos y controles: Propuesta de robustez de análisis para ciencias de la conducta
González, J. I. G., García, F. G. S., Loyo, L. M. S., & Santos, S. R.-D. L. (2023) · Educación y Salud Boletín Científico Instituto de Ciencias de la Salud Universidad Autónoma del Estado de Hidalgo · doi:10.29057/icsa.v11i22.10486
Titleman, M. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4457689
Tourassi, G. D., Shankar, M. A., & Wang, F. (2023) · OECD eBooks · doi:10.1787/0e1b4c2f-en
Eroom’s Law and the decline in the productivity of biopharmaceutical R&D
Scannell, J. W. (2023) · OECD eBooks · doi:10.1787/6f256d17-en · Cited by 5
The end of Moore’s Law? Innovation in computer systems continues at a high pace
Kressel, H. (2023) · OECD eBooks · doi:10.1787/63e48242-en · Cited by 3
Quantifying the “cognitive extent” of science and how it has changed over time and across countries
Milojević, S. (2023) · OECD eBooks · doi:10.1787/1f717652-en
Interpretability: Should – and can – we understand the reasoning of machine-learning systems?
Cartwright, H. (2023) · OECD eBooks · doi:10.1787/2d0478b9-en
OECD (2023) · OECD eBooks · doi:10.1787/f1262928-en
Azevedo, F. (2023) · ResearchEquals · doi:10.53962/r4qf-7peg
Ramadan, A., Chleilat, E., Martinez‐Navarro, H., et al. (2023) · The Journal of Physiology · doi:10.1113/jp284666
“However, the academic environment can hinder this by prioritising volume over quality due to fixed-term contracts and the need for attractive results, both of which are contributing to the ongoing reproducibility crisis (Begley & Ellis, 2012).”
Differentiation in Medical Practise using Sophisticated Data Analytics
Bhagat, A. K., & Chauhan, A. (2023) · International Conference on Advance Computing and Innovative Technologies in Engineering (ICACITE) · doi:10.1109/icacite57410.2023.10182429
Ju, J., de Oliveira, M. S., & Qiao, Y. (2023) · Food bioactive ingredients · doi:10.1007/978-3-031-33505-1_14
Laz, M.-A. D., Lampe, M., Connor, I., Shestachuk, D., Ludwig, M., Müller, U., Strauch, O. F., Suendermann, N., Lüth, S., & Kah, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.06.552188
A powerful replicability analysis of genome-wide association studiesPreprint
Li, Y., Lei, H., Wen, X., & Cao, H. (2023) · medRxiv · doi:10.1101/2023.09.04.23295018
A Systemic Review on Pyridine Derivative against Cancer and Tumor Cell-Line
Das, A., Sadhukhan, A., Mukherjee, S., Ghosh, A., Chakraborty, S., Bhattacharya, S., Roy, A., & Bhattacharjee, A. (2023) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2023.v81i02.020
de Guadalajara, U., González, J. I. G., García, F. G. S., de Jalisco, O. D. P. D. L. P. D. E., Madera-Carrillo, H., de Guadalajara, U., Aguayo, F. M., & Centro de Investigación en Matemáticas, A. (2022) · Revista Mexicana de Investigación en Psicología · doi:10.32870/rmip.v11i1.422
Open science interventions proposed or implemented to assess researcher impact: a scoping review
Ghannad, M., Armond, A. C. V., Ng, J. Y., Ayala, A. P., Khan, H., Grossman, M. R., Cormack, G. V., Pham, B., Leeflang, M., Bossuyt, P. M., et al. (2023) · F1000Research · doi:10.12688/f1000research.140556.1
Degen, P. M., & Medo, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.25.563901
Mochly‐Rosen, D., Grimes, K., Begley, C. G., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-34724-5_3
Self-citationOmniReprodubileCellAnalysis: a comprehensive toolbox for the analysis of cellular biology dataPreprint
Tortarolo, D., Pernice, S., Clapero, F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.07.565961
Data Analysis Frameworks for Investigating Behavioural Differences
Stevenson, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-45787-6_2
Cryopreservation and utility of cancer organoids and cartilage microtissues
Shajib, M. S. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.244762
The Digitalization of Science Computational Science as a Field of Inquiry in Design Science ResearchPreprint
Storey, V. C., & Baskerville, R. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4648196
Assessment of transparency indicators in Space MedicinePreprint
Bellomo, R. K., Zavalis, E. A., & Ioannidis, J. P. A. (2023) · medRxiv · doi:10.1101/2023.12.01.23299278
Study of Cytotoxic Responses of Anticancer Drug Cyclophosphamide
Mohale, V. B., Bharade, V. S., Wagh, V. S., Katariya, K. A., & Khan, N. (2023) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-14213
Challenges that Proprietary Research Poses for Meta-Analysis
GREEN, D. P., Leavitt, T., & Markovits, D. B. (2023) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780192868282.013.21
Investigating Factors Influencing Audiences’ Integration of Scientific EvidencePreprint
Schreiner, M. R., Rebholz, T. R., Pütter, J. Q., & Landrum, A. R. (2024) · doi:10.31234/osf.io/hkct6
Koch, E., & Plassmann, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00021-9
Gooden, A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1304950 · Cited by 2
Ethical Principles in Plastic Surgery Research
Prescher, H., & Vercler, C. J. (2024) · Seminars in Plastic Surgery · doi:10.1055/s-0043-1778045
NLRP3 inflammasome in sepsis: don’t overlook the small steps—they can make a big difference!
Belicard, F., Tarte, K., & Tadié, J. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae056
Osteopathie und evidenzbasierte Medizin, Teil 2: Kritik an der EBM
Luthin, D. (2024) · DO - Deutsche Zeitschrift für Osteopathie · doi:10.1055/a-2220-8344
“Eine Untersuchung aus dem Jahr 2012 kam gar zu dem Ergebnis, dass 47 von 53 „wichtigen“ präklinischen Studien in der Onkologie nicht reproduzierbar waren, obwohl die versuchten Replikatio-nen größtenteils von den ursprünglichen Autoren selbst durchgeführt worden waren [18].”
Success of Drug Development for Cancer Diseases: Radicalness and Structural HolesPreprint
Li, S., Azagra‐Caro, J. M., & Li, Y. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4779040
الفرضية المعلوماتية مقابل الفرضية الصفرية الإحصائية: دراسة الإحصاء الكلاسيكي مقابل الإحصاء البايزى
محمد, م. إ. م. (2024) · Al-Maǧallaẗ Al-Tarbawiyyaẗ Al-Šāmlaẗ · doi:10.21608/ejc.2024.348261
(2024) · Al-Maǧallaẗ Al-Tarbawiyyaẗ Al-Šāmlaẗ · doi:10.21608/ejc.2024.348256
Brūmele, B., Serova, E., Lupp, A., Suija, M., Mutso, M., & Kurg, R. (2024) · Antibodies · doi:10.3390/antib13020033 · Cited by 1
“It has even been suggested that poor antibodies are a significant reason why it has not been possible to replicate the scientific results of many landmark preclinical studies [3].”
BackgroundResultGREUGNY, E. T., Ratto, N., Éthève, L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.26.591317
Developing an in vitro repeat-dose approach to detect non-genotoxic carcinogens (NGCs)
Pritchard, D. (2024) · Cronfa (Swansea University) · doi:10.23889/suthesis.66287
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13829-4.00015-5
Software from publicly funded research should be free and open source for research
Whelan, B., Brock, K. K., & Li, Z. (2024) · Medical Physics · doi:10.1002/mp.17107
Boada, Y., Flores, M., Córdova, M., Flores, F. J., & Vignoni, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4356018/v1
Multistage Carcinogenesis: Cell and Animal Models
Kulesz-Martin, M. F., Ouyang, X., Ramin, S., Barling, A. N., Gallegos, J. R., Liu, Y., & Medler, T. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00085-1
Metadata
- Authors
- Begley, C. G., & Ellis, L. M.
- Affiliations
- Amgen (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Ellis, Lee M.
- Venue
- Nature
- Published
- 2012-03-28
- Volume
- 483
- Issue
- 7391
- Pages
- 531-533
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1987777080
- Semantic Scholar
- 1a81d3d1e8a983e0551edf485f4ac1a8cdd7fea4
- Cited by
- 2,979
- References
- 5
- Citations by year
- 2026: 106 · 2025: 116 · 2024: 127 · 2023: 169 · 2022: 179 · 2021: 206 · 2020: 236 · 2019: 255 · 2018: 262 · 2017: 271 · 2016: 283 · 2015: 262 · 2014: 226 · 2013: 133 · 2012: 62
- FWCI
- 210.63
- Type
- journal article
- Language
- en
- Update notices
- correction (2012-05-02)
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- preclinical cancer research, research standards, publication practices, research incentives, translational research, clinical trials
- MeSH terms
- Animals, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Research Design, Reproducibility of Results, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.